151 related articles for article (PubMed ID: 35018520)
61. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics.
Perwitasari DA; Gelderblom H; Atthobari J; Mustofa M; Dwiprahasto I; Nortier JW; Guchelaar HJ
Int J Clin Pharm; 2011 Feb; 33(1):33-43. PubMed ID: 21365391
[TBL] [Abstract][Full Text] [Related]
62. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Huybrechts KF; Hernández-Díaz S; Straub L; Gray KJ; Zhu Y; Patorno E; Desai RJ; Mogun H; Bateman BT
JAMA; 2018 Dec; 320(23):2429-2437. PubMed ID: 30561479
[TBL] [Abstract][Full Text] [Related]
63. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Markham A; Sorkin EM
Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
[TBL] [Abstract][Full Text] [Related]
64. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Burnette PK; Perkins J
Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
[TBL] [Abstract][Full Text] [Related]
65. Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Chaudhary NK; John RR; Boddu D; Mahasampath G; Nesadeepam N; Mathew LG
J Pediatr Hematol Oncol; 2019 May; 41(4):294-297. PubMed ID: 31026250
[TBL] [Abstract][Full Text] [Related]
66. Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting.
Choi EM; Lee MG; Lee SH; Choi KW; Choi SH
Anaesthesia; 2010 Oct; 65(10):996-1000. PubMed ID: 20707787
[TBL] [Abstract][Full Text] [Related]
67. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Mattiuzzi GN; Cortes JE; Blamble DA; Bekele BN; Xiao L; Cabanillas M; Borthakur G; O'Brien S; Kantarjian H
Cancer; 2010 Dec; 116(24):5659-66. PubMed ID: 21218459
[TBL] [Abstract][Full Text] [Related]
68. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.
Mora J; Valero M; DiCristina C; Jin M; Chain A; Bickham K
Pediatr Blood Cancer; 2019 Jun; 66(6):e27690. PubMed ID: 30900392
[TBL] [Abstract][Full Text] [Related]
69. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.
Peterson C; Hursti TJ; Börjeson S; Avall-Lundqvist E; Fredrikson M; Fürst CJ; Lomberg H; Steineck G
Support Care Cancer; 1996 Nov; 4(6):440-6. PubMed ID: 8961475
[TBL] [Abstract][Full Text] [Related]
70. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
71. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment.
LeBourgeois JP; McKenna CJ; Coster B; Feyer P; Franzén L; Goedhals L; Marzecki Z; Souhami L; Stewart A; Tønnessen F; Haigh C; Mitchell T; Wilkinson JR; Graham E
Clin Oncol (R Coll Radiol); 1999; 11(5):340-7. PubMed ID: 10591823
[TBL] [Abstract][Full Text] [Related]
72. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
[TBL] [Abstract][Full Text] [Related]
73. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
74. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
[TBL] [Abstract][Full Text] [Related]
75. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
76. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
[TBL] [Abstract][Full Text] [Related]
77. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
78. Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting.
Kim MS; Lee JR; Choi EM; Kim EH; Choi SH
Yonsei Med J; 2015 Sep; 56(5):1415-20. PubMed ID: 26256989
[TBL] [Abstract][Full Text] [Related]
79. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Dranitsaris G; Mazzarello S; Smith S; Vandermeer L; Bouganim N; Clemons M
Support Care Cancer; 2016 Apr; 24(4):1563-9. PubMed ID: 26381427
[TBL] [Abstract][Full Text] [Related]
80. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
